Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma
May 22, 2023 08:00 ET
|
Rain Oncology Inc.
– The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care – – The median PFS was 3.6 months for milademetan versus 2.2 months for trabectedin with...
Rain Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Progress
May 11, 2023 16:05 ET
|
Rain Oncology Inc.
– Quarter-end cash position of $110 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2...
Rain Oncology to Report First Quarter 2023 Financial Results and Highlights Recent Progress on May 11, 2023
April 24, 2023 08:00 ET
|
Rain Oncology Inc.
NEWARK, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product...
Rain Oncology Announces Collaborator Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023
April 05, 2023 08:00 ET
|
Rain Oncology Inc.
NEWARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate,...
Rain Oncology Announces Oral Presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress
March 21, 2023 05:50 ET
|
Rain Oncology Inc.
NEWARK, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate,...
Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
March 09, 2023 16:05 ET
|
Rain Oncology Inc.
– Year-end cash position of $130.5 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2...
Rain Oncology to Present At Oppenheimer 33rd Annual Healthcare Conference
March 07, 2023 08:00 ET
|
Rain Oncology Inc.
NEWARK, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate,...
Rain Oncology to Report Fourth Quarter and Full Year 2022 Financial Results and Highlights of Recent Progress on March 9, 2023
February 23, 2023 08:00 ET
|
Rain Oncology Inc.
NEWARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product...
Rain Oncology to Participate in the 2023 Citi Virtual Oncology Leadership Summit
February 09, 2023 08:00 ET
|
Rain Oncology Inc.
NEWARK, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate,...
UPDATE – Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference
January 31, 2023 16:27 ET
|
Rain Oncology Inc.
NEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Rain Oncology (NASDAQ: RAIN), the company is updating their presentation date and time to Thursday, February 9,...